Jointly provided by
|
This activity is supported by independent educational grants from Biogen, Bristol Myers Squibb and Sanofi Genzyme.
|
Thursday, October 22, 2020
6:30 PM – 8:00 PM ET
|
|
Click here to register!
|
|
Learn About
|
- How the rapidly evolving treatment landscape challenges the ability of clinicians and health systems to identify the optimal balance between safety, efficacy, and overall value when making MS treatment decisions
|
Expert Faculty Presenters
|
|
|
|
|
Theresa (Teri) Danner, PharmD, CSP, MSCS
Therapy Lead, Multiple Sclerosis
Optum Specialty Pharmacy
|
|
John Fox, MD, MHA
Chief Boundary Spanner
Foxworthy Healthcare Consulting, LLC
|
|
Amanda Montague, Ed.M.
Vice President of Education & Healthcare Relations
Multiple Sclerosis Association of America (MSAA)
|
|
Mitzi Joi Williams, MD
Founder and CEO
Joi Life Wellness Group, LLC
|
|
|
|
Who Should Attend?
|
This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, members of the AMCP, and other managed health care professionals attending AMCP Nexus 2020 virtually.
|
|
Statement of Need/Program Overview
|
Multiple sclerosis (MS) is associated with a broad spectrum of comorbid conditions including cardiovascular disease and mental health issues that exert a significant influence on patient morbidity, mortality, and quality of life. Comorbidity is associated with a longer delay between MS symptom onset and diagnosis, more severe disability at diagnosis even after accounting for diagnostic delays, greater disability progression, increased health-care utilization, and higher mortality. More than a dozen disease-modifying therapies (DMTs) are now available for the treatment of MS with several additional novel therapies in late stage development. The abundance of choice can lead to therapeutic inertia or the absence of treatment initiation or intensification when therapeutic goals are unmet. This symposium highlights opportunities for managed care and specialty pharmacy professionals to enhance the management of patients with MS by implementing and/or recommending evidence-driven practices based on current clinical trial data.
|
|
Educational Objectives
|
At the conclusion of this activity, participants should be able to demonstrate improved ability to:
- Discuss where current and emerging therapies fit into the MS management algorithm
- Review the importance of identifying and treating comorbid conditions commonly observed in patients with MS
- Apply strategies to identify and overcome therapeutic inertia in MS treatment
- Employ treatment optimization approaches to balance costs with improved outcomes in MS management
|
|
Agenda
|
Date and Time
Thursday, October 22, 2020
6:30 PM – 8:00 PM ET
|
|
6:30 PM
|
Pre-Activity Learning Assessment and Opening Comments/Overview
John Fox, MD, MHA
|
|
6:35 PM
|
Assessing Current and Emerging Therapies and How They Fit into the MS Treatment Algorithm
Mitzi Joi Williams, MD
|
|
6:55 PM
|
MS Medical Management Recommendations for Health Plans
John Fox, MD, MHA
|
|
7:15 PM
|
Patient-Centric Strategies to Optimize MS Outcomes
Teri Danner, PharmD, CSP, MSCS
|
|
7:35 PM
|
Shared Decision-Making: Aligning MS Care with Patient Needs
Amanda Montague, Ed.M.
|
7:50 PM
|
Audience Q&A Session
|
|
8:00 PM
|
Key Takeaways and Closing Comments; Post-Activity Assessment and Evaluation
|
|
Accreditation Information
|
|
Joint Accreditation Statement |
 |
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
|
|
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008162-9999-20-2297-L01-P
Type of Activity: Application
|
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.
Fee Information
There is no fee for this educational activity.
If you have any questions, please call (215) 619-8812 or email info@impactedu.net.
|
|
